恒瑞医药药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with apple acid famitinib capsules, for first-line treatment of recurrent or metastatic cervical cancer patients [1] Group 1 - The company and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have had their application accepted for a new treatment regimen [1] - Injection Karilizumab has been approved for multiple indications in China, including treatment for advanced hepatocellular carcinoma patients who have previously received sorafenib and/or oxaliplatin-based chemotherapy since March 2020 [1] - Apple acid famitinib capsules were approved in May 2025 for use in combination with injection Karilizumab for recurrent or metastatic cervical cancer patients who failed platinum-based chemotherapy but have not received bevacizumab treatment [1]